Fig. 2From: Clinical features and treatment outcomes of pediatric Langerhans cell histiocytosis with macrophage activation syndrome-hemophagocytic lymphohistiocytosisComparison of treatment response of MAS-HLH indexes between patients treated with dabrafenib and second-line chemotherapy. *P < 0.05, **P < 0.01, ***P < 0.001Back to article page